Lantheus Holdings Inc
NASDAQ:LNTH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
51.07
123.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Lantheus Holdings Inc
Lantheus Holdings Inc
Cash & Cash Equivalents
Lantheus Holdings Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cash & Cash Equivalents
$866.4m
|
CAGR 3-Years
112%
|
CAGR 5-Years
62%
|
CAGR 10-Years
41%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Cash & Cash Equivalents
$299.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Cash & Cash Equivalents
$296m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cash & Cash Equivalents
$312.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cash & Cash Equivalents
$1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
19%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cash & Cash Equivalents
$523.1m
|
CAGR 3-Years
97%
|
CAGR 5-Years
70%
|
CAGR 10-Years
55%
|
|
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a dynamic healthcare company specializing in the development, manufacture, and commercialization of innovative diagnostic imaging agents, particularly in the field of nuclear medicine. Founded in 1956, the company has established a solid reputation for improving patient care through advanced diagnostics, helping healthcare providers make more informed decisions. Lantheus is perhaps best known for its flagship products, including nuclear imaging agents like Pylarify, used in the detection of prostate cancer. With a robust pipeline of novel radiopharmaceuticals in various stages of development, the company is strategically positioned to address unmet needs in diagnostics and therapeutics, thereby enhancing both patient outcomes and shareholder value. For investors, Lantheus represents a compelling opportunity, particularly as the demand for precision medicine continues to grow. With healthcare trends increasingly leaning towards personalized treatment, Lantheus is poised to grow through strategic partnerships, expanding market access, and leveraging new technologies. The company's commitment to innovation is underscored by its recent achievements and promising clinical trials, which have the potential to reshape the landscape of cancer diagnostics and treatment. As Lantheus Holdings continues to expand its portfolio and strengthen its market presence, investors can look forward to both solid financial performance and meaningful contributions to the evolving field of medical diagnostics.
See Also
What is Lantheus Holdings Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
866.4m
USD
Based on the financial report for Sep 30, 2024, Lantheus Holdings Inc's Cash & Cash Equivalents amounts to 866.4m USD.
What is Lantheus Holdings Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
41%
Over the last year, the Cash & Cash Equivalents growth was 41%. The average annual Cash & Cash Equivalents growth rates for Lantheus Holdings Inc have been 112% over the past three years , 62% over the past five years , and 41% over the past ten years .
You don't have any saved screeners yet
